Celebrex, Celecoxib Newswire

Celebrex, Celecoxib Newswire

Comprehensive Real-Time News Feed for Celebrex, Celecoxib (generic).

Results 1 - 20 of 120 in Celebrex, Celecoxib (generic)

  1. Flexion Therapeutics: Novel Knee Osteoarthritis Therapy With Upcoming CatalystRead the original story w/Photo

    Yesterday | Seeking Alpha

    The company's flagship product candidate, Zilretta is an injectable, extended-release, intra-articular formulation of triamcinolone acetonide, a corticosteroid that is being developed for the treatment of patients with knee osteoarthritis. Our first price target for the common stock is $39 using enterprise DCF method .

    Comment?

  2. Taking your medications in safe wayRead the original story w/Photo

    Wednesday Feb 15 | Cleveland Daily Banner

    Prescription medications are supposed to make us feel better, but many people are unintentionally becoming sicker and putting themselves at risk without even knowing it because of the way they are Prescription medications are supposed to make us feel better, but many people are unintentionally becoming sicker and putting themselves at risk without even knowing it because of the way they are taking their medications. With more than 40 percent of seniors taking five or more prescription medications, it's easy to see why a National Institute of Health study also found that 55 percent of them take their medications incorrectly.

    Comment?

  3. Marina Biotech Completes Share Issuance At A Valuation Of $0.29 Per ShareRead the original story

    Monday Feb 13 | BioSpace

    Marina Biotech, Inc. , a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, today announced that it has entered into two privately negotiated transactions pursuant to which it will issue an aggregate of approximately 6.15 million shares of its common stock for an effective price per share of $0.29. As a result of such transactions, the company will reduce the aggregate amount of its outstanding payables to its service providers by approximately $1.78 million.

    Comment?

  4. Kitov CEO questioned over Ph III data concernsRead the original story w/Photo

    Thursday Feb 9 | Drug Researcher

    Kitov Pharmaceuticals Holdings Ltd. is standing by the validity of its Phase III clinical trial data results as investigations begin. The company's CEO Mr. Isaac Israel, was detained for questioning earlier this week before being released later in the day " under certain limited restrictive terms established by a court ," Kitov said in a statement.

    Comment?

  5. How BioVie, Conatus and PhaseRX Tackle Liver DiseasesRead the original story w/Photo

    Wednesday Feb 8 | GuruFocus.com

    For investors looking for new disruptive biotech companies in the liver space it is worth taking a close look at BioVie Inc. . BioVie's lead asset BIV-201 is going after major indications in the liver space, which is in need of great new therapies.

    Comment?

  6. Marina Biotech Announces A License Agreement To SMARTICLESRead the original story

    Tuesday Feb 7 | BioSpace

    Marina Biotech, Inc. a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension, and cancer, today announced that they have entered into a license agreement regarding the Company's SMARTICLES platform for the delivery of nanoparticles including small molecules, peptides, proteins and biologics. This represents the first time that the Company's SMARTICLES technologies have been licensed in connection with nanoparticles delivering small molecules, peptides, proteins and biologics.

    Comment?

  7. Taking anti-inflammatories during cold or flu may boost heart attack riskRead the original story w/Photo

    Thursday Feb 2 | CBC News

    Commonly used anti-inflammatory painkillers may increase the risk of heart attacks when taken during a cold or flu, a new study suggests. The study was based on data on nearly 10,000 patients with an average age of 73 who were hospitalized for a heart attack, also called acute myocardial infarction, in Taiwan from 2005 to 2011.

    Comment?

  8. Common Painkillers Don't Ease Back Pain, Study FindsRead the original story w/Photo

    Thursday Feb 2 | HON

    The researchers estimated that only one in six people gained a benefit from taking these nonsteroidal anti-inflammatory drugs . Meanwhile, previous research has suggested that another common painkiller, Tylenol , isn't very useful either, the study authors added.

    Comment?

  9. Worried about back pain behind bars, she smuggled 199 pills in body cavityRead the original story w/Photo

    Wednesday Feb 1 | MLive.com

    Lynette Sue Humphrey said in court Tuesday that she tried smuggling pills into jail for her own back pain, rather than selling them to other inmates. Humphrey, 55, was sentenced Jan. 31 to a term of 12 months in jail for smuggling contraband into jail.

    Comment?

  10. Kitov Granted Notice Of Allowance From U.S. Patent & Trademark Office For KIT-302Read the original story

    Tuesday Jan 31 | BioSpace

    Kitov Pharmaceuticals Holdings Ltd. , an innovative biopharmaceutical company, announced today that the U.S. Patent and Trademark Office has issued a Notice of Allowance to the Company related to claims expanding the patent coverage for its lead drug candidate, KIT-302, to include oral dosage compositions containing both amlodipine and celecoxib. "This Notice of Allowance should result in the issuance of an additional patent, which is expected to further strengthen Kitov's proprietary position and long-term U.S. market exclusivity for our lead compound, KIT-302, creating a higher barrier to entry for potential competitors.

    Comment?

  11. Dow 30 Earnings: Pfizer Fourth Quarter 2016Read the original story

    Tuesday Jan 31 | Value Line

    The year-over-year increase in profits was driven primarily by reduced spending on production and SG&A , partially offset by higher R&D costs and lower revenues . Meanwhile, adjusted earnings, which exclude one-time gains, charges, and other nonrecurring items, and are more closely followed by Wall Street, came in at $0.47 a share, versus $0.53 in 2015.

    Comment?

  12. Medical Mix-ups: Don't Confuse These DrugsRead the original story w/Photo

    Jan 24, 2017 | News Max

    More than 4 billion prescriptions are written for Americans every year. That's an average of 13 for every man, woman, and child in the country, according to the Kaiser Family Foundation.

    Comment?

  13. Malaysia Healthcare, Regulatory and Reimbursement Landscape Report 2016-2020 - Research and MarketsRead the original story

    Jan 18, 2017 | Customer Interaction Solutions

    Research and Markets has announced the addition of the "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Malaysia" report to their offering. Malaysia's healthcare market has huge potential for growth.

    Comment?

  14. Billig Apotek P N tet Overnight * Ink p Celecoxib L gt Pris * B sta p generikaRead the original story

    Jan 16, 2017 | Hernando Today

    Var man kan kopa Celebrex Nederlanderna. Generic Celebrex is used for treating rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, juvenile arthritis or menstrual pain. It is also used in familial adenomatous polyposis (FAP) to decrease the number of polyps (growths) in the rectal area.

    Comment?

  15. University of Pennsylvania Should Rethink Over-Hyped Press ReleasesRead the original story

    Jan 10, 2017 | BioSpace

    Back in 2012, a press release was issued by the Perelman School of Medicine at the University of Pennsylvania which had profound medical implications for treating arthritic pain in patients with heart disease. Entitled "NSAIDs and Cardiovascular Risk Explained, According to Studies from the Perelman School of Medicine," the release was quite damning about the use of a certain class of non-steroidal anti-inflammatory drugs - the COX-2 inhibitors - not just in patients with cardiovascular risk but even arthritis patients without such risk.

    Comment?

  16. Addex Therapeutics ADX71441 Demonstrates Statistically Significant...Read the original story

    Jan 8, 2017 | BioSpace

    Geneva, Switzerland, 9 January 2017 - Addex Therapeutics , announced today that ADX71441, a positive allosteric modulator of the gamma-aminobutyric acid subtype B receptor demonstrated statistically significant efficacy in a highly translational preclinical model of chronic osteoarthritis pain. ADX71441 and celecoxib, a COX-2 selective nonsteroidal anti-inflammatory drug were studied in the monosodium iodoacetate model of chronic osteoarthritis pain for their anti-hyperalgesic effects.

    Comment?

  17. Bioiberica Release: New Study Finds Chondroitin Sulfate Superior To...Read the original story

    Jan 8, 2017 | BioSpace

    Bioiberica is pleased to share the positive results of the MOSAIC Study regarding the use of chondroitin sulfate for knee osteoarthritis as published in the Arthritis Research and Therapy journal. For the first time in a 2-year randomized controlled trial using quantitative MRI , the study concluded that chondroitin sulfate CS b-BioactiveA is superior to an anti-inflammatory drug for delaying the progression of knee osteoarthritis.

    Comment?

  18. Addex ADX71441 Demonstrates Statistically Significant Efficacy in a...Read the original story

    Jan 8, 2017 | P&T Community

    Addex Therapeutics , announced today that ADX71441, a positive allosteric modulator of the gamma-aminobutyric acid subtype B receptor demonstrated statistically significant efficacy in a highly translational preclinical model of chronic osteoarthritis pain. ADX71441 and celecoxib, a COX-2 selective nonsteroidal anti-inflammatory drug were studied in the monosodium iodoacetate model of chronic osteoarthritis pain for their anti-hyperalgesic effects.

    Comment?

  19. Taking multiple medications? You may also be taking excess risks.Read the original story w/Photo

    Jan 6, 2017 | The Washington Post

    Lugging every pill you take to your next doctor's appointment or trip to the pharmacist might seem like overkill, but it could save your life - especially if you take multiple drugs or supplements. In fact, regularly taking five or more medications - something many Americans do - often does more harm than good, especially if you're not closely monitored by a health-care provider.

    Comment?

  20. Is Medication Risk Worth the Benefit?Read the original story w/Photo

    Dec 23, 2014 | Genesee Valley Pennysaver

    DEAR DR. ROACH: I am a 76-year-old woman with diabetes. My body, as I have been told, is bad with arthritis, for which I have been prescribed Celebrex.

    Comment?